Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Earnings Call

Lupin Earnings Call: Key Takeaways

Lupin reported strong Q4 FY26 results with sales reaching ₹73,919 mn, up 33% YoY, driven by a 55% surge in North American markets.

Highlights
Revenue growth32.9% YoY for Q4 FY26; 23.9% for full year FY26.
MarginsEBITDA margin improved to 29.4% in Q4 FY26 from 23.2% YoY.
Demand visibilityStrong US demand for complex products like Tiotropium and Albuterol.
Management confidenceHigh confidence in complex generic and biosimilar pipeline strategy.

Growth

Q4 FY26 Revenue grew 32.9% YoY; EBITDA increased 68.0% YoY; Net Income rose 89.0% YoY.

Outlook

Plan to launch 20+ products in India FY27; targeting 100+ new product launches in US by FY31.

Risks

Price erosion in Albuterol and US base business competition; regulatory remediation ongoing at Pithampur Unit II.

Source

Earnings Call filed with BSE, NSE: LUPIN. Summary written with AI assistance from the document.

Read the document ↗

Lupin Ltd: key numbers

Share price
₹2,092.00
Market cap
₹95,665 Cr
Revenue (annual)
₹27,958 Cr
Net profit (annual)
₹5,333 Cr
P/E (TTM)
17.3×Sector 50.4×
Promoter holding
46.85%-0.01% QoQ
FII holding
22.42%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Lupin Ltd

All →
16:14 IST BSE
Employee Stock Options

Lupin Employee Stock Options

Lupin Ltd allotted 24,111 equity shares to employees following the exercise of vested stock options under the company's ESOP schemes.

17:38 IST NSE
Product Launch

Lupin Product Launch

Lupin received US FDA approval for Modafinil Tablets, USP, a generic version of Provigil. This regulatory approval enables the company to market the drug in the U.S.